Skip to main content
    S

    Soleno Therapeutics Inc (SLNO)

    Official site

    BIOTECHNOLOGY

    $53.01
    +0.00 (+0.00%)

    Last updated: May 19, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(20/38)
    Avg Surprise
    +17.37%

    Upcoming Estimates

    Period ending Jun 30, 2026
    EPS Consensus$0.93
    Range$0.78 - $1.26
    8 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$0.98-4.7%
    60d ago$0.94-0.6%
    30d ago$0.94-0.4%
    7d ago$0.94-0.4%
    Current$0.93
    Revenue Consensus
    $112M
    Range$106M - $120M
    7 analysts
    Period ending Sep 30, 2026
    EPS Consensus$1.06
    Range$0.78 - $1.55
    8 analysts
    EPS RevisionsNo revisions (7d)
    0
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$1.13-5.8%
    60d ago$1.05+1.3%
    30d ago$1.060.0%
    7d ago$1.060.0%
    Current$1.06
    Revenue Consensus
    $123M
    Range$116M - $134M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$1.22---
    Sep 26EST
    		-$1.06---
    Jun 26EST
    		-$0.93---
    Mar 26
    Reported May 7
    		$0.59$0.68-13.24%Miss+162.1%
    Dec 25
    Reported Feb 25
    		$0.80$0.21+272.09%Beat+163.0%
    Sep 25
    Reported Nov 4
    		$0.47$0.05+840.00%Beat+125.7%
    Jun 25
    Reported Aug 6
    		$-0.09N/A+85.94%Beat+84.2%
    Mar 25
    Reported May 7
    		$-0.95$-0.93-2.43%Miss-61.0%
    Dec 24
    Reported Feb 27
    		$-1.27$-1.08-17.91%Miss-284.8%
    Sep 24
    Reported Nov 6
    		$-1.83$-0.63-190.48%Miss-92.6%
    Jun 24
    Reported Aug 7
    		$-0.57$-0.60+5.00%Beat+29.6%
    Mar 24
    Reported May 9
    		$-0.59$-0.37-59.46%Miss+33.0%
    Dec 23
    Reported Mar 6
    		$-0.33$-0.27-22.22%Miss+43.1%
    Sep 23
    Reported Nov 7
    		$-0.95$-0.58-63.79%Miss-25.0%
    Jun 23
    Reported Aug 8
    		$-0.81$-0.83+2.41%Beat+10.0%
    Mar 23
    Reported May 9
    		$-0.88$-0.72-22.22%Miss+18.5%
    Dec 22
    Reported Mar 21
    		$-0.58$-0.80+27.50%Beat+3.3%
    Sep 22
    Reported Nov 9
    		$-0.76$-0.91+16.48%Beat+49.3%
    Jun 22
    Reported Aug 10
    		$-0.90$-0.90+0.00%Beat+57.1%
    Mar 22
    Reported May 10
    		$-1.08$-1.05-2.86%Miss+34.5%
    Dec 21
    Reported Mar 31
    		$-0.60N/A+52.76%Beat+0.0%
    Sep 21
    Reported Nov 10
    		$-1.50$-1.65+9.09%Beat+9.1%
    Jun 21
    Reported Jul 28
    		$-2.10$-1.60-31.25%Miss+12.5%
    Mar 21
    Reported May 5
    		$-1.65$-1.15-43.48%Miss+15.4%
    Dec 20
    Reported Mar 3
    		$-0.60$-1.05+42.86%Beat+88.9%
    Sep 20
    Reported Nov 10
    		$-1.65$-1.30-26.92%Miss-466.7%
    Jun 20
    Reported Aug 10
    		$-2.40$-3.07+21.82%Beat+48.4%
    Mar 20
    Reported May 12
    		$-1.95$-2.95+33.90%Beat+40.9%
    Dec 19
    Reported Mar 4
    		$-5.40$-2.40-125.00%Miss-350.0%
    Sep 19
    Reported Nov 13
    		$0.45N/A+118.75%Beat+123.1%
    Jun 19
    Reported Aug 7
    		$-4.65$-2.62-77.48%Miss+13.9%
    Mar 19
    Reported May 13
    		$-3.30$-4.35+24.14%Beat+58.5%
    Dec 18
    Reported Mar 18
    		$-1.20N/A+72.41%Beat-126.4%
    Sep 18
    Reported Nov 15
    		$-1.95$-3.22+39.44%Beat+45.8%
    Jun 18
    Reported Aug 14
    		$-5.40$-3.67-47.14%Miss-20.0%
    Mar 18
    Reported Apr 2
    		$-7.95$-3.45-130.43%Miss+3.6%
    Dec 17
    Reported Mar 16
    		$-0.53$-0.23-130.43%Miss+95.6%
    Sep 17
    Reported Nov 14
    		$-3.60$-3.75+4.00%Beat-
    Jun 17
    Reported Aug 11
    		$-4.50$-6.00+25.00%Beat-
    Mar 17
    Reported May 11
    		$-8.25$-5.25-57.14%Miss-
    Dec 16
    Reported Mar 15
    		$-12.00$-17.25+30.43%Beat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$52.97
    SMA 20$52.89
    SMA 50$46.05
    SMA 200$52.23
    EMA 10$52.93
    EMA 20$52.17
    EMA 50$48.71
    EMA 200$52.14

    MACD

    Line: 1.47Signal: 1.95Hist: -0.48

    ADX

    ADX: 50.6+DI: 47.2-DI: 14.3

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down8.0
    PSAR$52.82

    Bollinger Bands

    Upper Band$53.08
    Lower Band$52.70
    %B Position73%(Middle)
    Band Width0.81

    RSI (14-Day)

    Overbought
    77.7

    Momentum Oscillators

    Stoch %K100.0
    Stoch %D98.6
    Williams %RN/A
    ROC (10d)0.2%
    Momentum0.09
    CCI (20d)104.2
    MFI (14d)85.3

    Volatility Measures

    ATR (14d)$0.38(0.7%)
    StdDev (20d)0.10
    Hist Vol1.1%(Low)

    Volume Flow

    VWAP$53.01
    OBV51.5M
    AD Line-6.8M
    CMF (20d)0.257

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol RatioN/A
    VWMA (20d)$52.88

    Pivot Points

    R3$53.01
    R2$53.01
    R1$53.01
    Pivot Point$53.01
    S1$53.01
    S2$53.01
    S3$53.01

    Advanced Oscillators

    TSI55.95
    Ultimate Osc58.3
    KST214.22

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$94.60M$91.73M$66.02M$32.66M$0$0$0$0$0$3.45M$0$0
    Cost of Revenue$1.20M$863,000$1.14M$696,000$0N/A$0$0$0$489,000$0$0
    Gross Profit$93.41M$90.87M$64.88M$31.96M$0N/A$0$0$0$2.96M$0$0
    Operating Expenses$62.13M$51.29M$42.77M$38.49M$45.74M$59.12M$80.21M$24.87M$23.48M$13.91M$10.38M$8.62M
    R&D$11.27M$9.56M$8.40M$9.15M$13.52M$21.49M$30.14M$12.34M$14.60M$8.69M$6.04M$5.14M
    SG&A$50.37M$40.88M$33.75M$28.24M$29.26M$37.30M$49.20M$10.89M$8.47M$4.14M$3.32M$3.17M
    Operating Income$31.28M$39.58M$22.11M$-6,525,000$-45,743,000$-59,116,000$-80,212,000$-24,868,000$-23,475,000$-13,910,000$-10,382,000$-8,623,000
    Interest Income$4.93M$5.13M$5.30M$3.19M$3.33M$3.37M$3.60M$3.01M$2.08M$2.14M$174,000$147,000
    Interest Expense$1.29M$1.35M$1.39M$1.38M$1.36M$231,000$0$0$0$0$479,000$0
    Income Before Tax$34.91M$43.36M$26.01M$-4,708,000$-43,773,000$-55,982,000$-76,616,000$-21,854,000$-21,398,000$-11,296,000$-10,861,000$-8,475,000
    Income Tax Expense$3.54M$0$0$0$0$0$0$0$0$0$0$0
    Net Income$31.38M$43.36M$26.01M$-4,708,000$-43,773,000$-55,982,000$-76,616,000$-21,854,000$-21,398,000$-11,296,000$-10,861,000$-8,475,000
    EBITDA$31.58M$38.90M$22.25M$-6,988,000$-46,211,000$-60,013,000$-81,621,000$-25,487,000$-23,458,000$-13,421,000$-10,545,000$-8,133,000
    EBIT$31.28M$39.58M$22.11M$-6,525,000$-45,743,000$-59,116,000$-80,212,000$-24,868,000$-23,475,000$-13,910,000$-11,035,000$-8,622,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SLNO

    News

    Bronstein, Gewirtz & Grossman, LLC Encourages Soleno Therapeutics, Inc. (SLNO) Stockholders to Inquire about Securities Investigation

    Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ:SLNO) on behalf of investors who purchased securities prior to May 26...

    ACCESS Newswire•8/7/26•Bearish

    Soleno Therapeutics, Inc. (SLNO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

    Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ:SLNO) concerning alleged corporate wrongdoing. The firm is encouraging stockholders who purchased Soleno...

    ACCESS Newswire•8/5/26•Bearish

    Bronstein, Gewirtz & Grossman, LLC Is Investigating Soleno Therap

    Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ: SLNO) on behalf of investors who purchased securities prior to May 26, 2025...

    The National Law Review•8/3/26•Somewhat-Bearish

    Neurocrine Biosciences (NBIX) quantifies Soleno acquisition and VYKAT XR impact

    Neurocrine Biosciences (NBIX) filed an amendment detailing the financial impact of its Soleno Therapeutics acquisition...

    Stock Titan•8/1/26•Somewhat-Bullish

    Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

    Neurocrine Biosciences reported a 39% year-over-year increase in total second-quarter 2026 revenue, reaching $959 million...

    TradingView•7/30/26•Neutral

    SLNO Competitors

    CompanyTicker
    Arcus Biosciences IncRCUS
    Dyne Therapeutics IncDYN
    Denali Therapeutics IncDNLI
    Privia Health Group IncPRVA
    Enliven Therapeutics Inc.ELVN
    Aveanna Healthcare Holdings IncAVAH
    Celcuity LLCCELC
    Neogen CorporationNEOG

    Sector: Healthcare

    SLNO Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    122.4%
    EPS estimate (fiscal period ending Jun 30, 2026)
    $0.93
    Estimate revisions (30 days, fiscal period ending Jun 30, 2026)
    0 up, 3 down

    Frequently Asked Questions About SLNO

    Does SLNO pay dividends?

    Soleno Therapeutics Inc (SLNO) does not currently pay a regular dividend.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In